FOXO4-DRI (Proxofim)

1. Overview

FOXO4-DRI (also known as Proxofim) is a 46-amino-acid synthetic peptide engineered using the D-retro-inverso (DRI) strategy to selectively eliminate senescent cells -- a therapeutic approach known as senolysis. The peptide was designed by Peter de Keizer and colleagues, initially at Erasmus University Medical Center (Erasmus MC) in Rotterdam, the Netherlands, and was first described in a landmark 2017 publication in the journal Cell [1]. The name "DRI" denotes D-retro-inverso: the peptide sequence is reversed compared to the parent FOXO4 fragment and synthesized entirely from D-amino acids, the mirror images of the naturally occurring L-amino acids. This chemical modification confers marked resistance to proteolytic degradation by endogenous proteases, which have evolved to cleave bonds between L-amino acids, while preserving the three-dimensional spatial arrangement of amino acid side chains necessary for biological activity [1][3].

FOXO4-DRI targets a specific protein-protein interaction between the forkhead box O4 (FOXO4) transcription factor and the tumor suppressor p53 that is uniquely upregulated in senescent cells. By competitively disrupting this interaction, FOXO4-DRI releases p53 from nuclear sequestration, allowing it to translocate to mitochondria and trigger intrinsic apoptosis exclusively in senescent cells, while leaving healthy proliferating and quiescent cells unaffected [1][2][3]. This selectivity distinguishes FOXO4-DRI from other senolytic compounds such as navitoclax and dasatinib+quercetin, which target more broadly expressed anti-apoptotic pathways and can cause significant off-target effects including thrombocytopenia [12][13][20].

The compound has a molecular weight of approximately 5,358 Da and carries the CAS registry number 2460055-10-9. As of 2026, FOXO4-DRI remains entirely in the preclinical research stage, with no completed human clinical trials. Peter de Keizer's group (now at UMC Utrecht) has expressed intent to pursue clinical safety studies, with glioblastoma multiforme proposed as an initial indication [2].

Type

Synthetic D-retro-inverso peptide (all-D-amino acids, reversed sequence)

Molecular Weight

~5,358 Da (46 amino acids)

Sequence

H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH (all-D)

Target

FOXO4-p53 protein-protein interaction in senescent cells

Half-life

Extended vs. L-peptides (protease-resistant); exact pharmacokinetic data not published

Route

Intraperitoneal or intravenous injection (research)

Developer

Peter de Keizer lab, Erasmus MC / UMC Utrecht

CAS Number

2460055-10-9

FDA Status

Not approved; preclinical only

2. Cellular Senescence: The Biological Context

Cellular senescence is a state of irreversible cell cycle arrest triggered by various stressors, including telomere shortening (replicative senescence), oncogene activation (oncogene-induced senescence), DNA damage (including from chemotherapy and radiation), and oxidative stress [9][10]. Senescent cells are characterized by upregulation of the cyclin-dependent kinase inhibitors p16^INK4a and p21^CIP1/WAF1, resistance to apoptosis, altered nuclear morphology, elevated senescence-associated beta-galactosidase (SA-beta-gal) activity, and secretion of a complex cocktail of pro-inflammatory cytokines, chemokines, growth factors, and matrix metalloproteinases collectively termed the senescence-associated secretory phenotype (SASP) [9][18].

While senescence serves as an essential tumor-suppressive mechanism by halting proliferation of damaged cells, the accumulation of senescent cells with age becomes detrimental. The persistent SASP drives chronic sterile inflammation ("inflammaging"), disrupts tissue architecture, promotes extracellular matrix degradation, and paradoxically facilitates tumorigenesis in neighboring cells through paracrine signaling [10][18]. Landmark studies by Baker et al. demonstrated that genetic clearance of p16^INK4a-positive senescent cells in INK-ATTAC transgenic mice delayed age-related pathologies and extended median lifespan by approximately 25%, establishing senescent cell accumulation as a causal driver of aging phenotypes rather than merely a correlate [11].

These findings catalyzed intense interest in pharmacological senolytic agents -- compounds capable of selectively killing senescent cells. The first-generation senolytics dasatinib+quercetin (D+Q) were identified through a bioinformatics approach targeting senescent cell anti-apoptotic pathways (SCAPs) [12], while navitoclax (ABT-263) was repurposed from oncology as a BCL-2/BCL-XL/BCL-W inhibitor [13][20]. FOXO4-DRI emerged as a mechanistically distinct senolytic targeting the FOXO4-p53 axis rather than the BCL-2 family [1].

3. Mechanism of Action

3.1 The FOXO4-p53 Axis in Senescent Cell Viability

The mechanism of FOXO4-DRI is rooted in the discovery that FOXO4 plays a critical and specific role in maintaining the viability of senescent cells [1][3]. Upon DNA damage, both FOXO4 and p53 are recruited to promyelocytic leukemia (PML) nuclear bodies -- subnuclear structures that serve as hubs for DNA damage signaling and repair. Within these PML bodies, FOXO4 physically binds to p53 through two distinct interaction surfaces: the FOXO4 forkhead domain (FHD) engages the p53 transactivation domain (TAD), while the FOXO4 C-terminal transactivation domain (CR3) contacts the p53 DNA-binding domain (DBD) [3][15][22].

This dual-surface interaction has profound functional consequences. By sequestering p53 in PML nuclear bodies, FOXO4 redirects p53 transcriptional activity toward senescence-promoting genes -- most notably the CDK inhibitor p21^CIP1/WAF1 -- while simultaneously preventing p53 from initiating apoptotic programs [1][3]. In essence, FOXO4 acts as a molecular switch that tips the p53 response from cell death toward cell survival-in-senescence. This mechanism explains a long-standing puzzle: why senescent cells, despite harboring extensive DNA damage and activated p53, resist apoptosis rather than undergoing programmed cell death [2].

Crucially, FOXO4 expression is markedly upregulated in senescent cells compared to normal proliferating or quiescent cells. FOXO4 foci colocalize extensively with p53 in DNA-SCARS (DNA segments with chromatin alterations reinforcing senescence) within PML bodies specifically in senescent cells [1]. This differential expression pattern provides the basis for the selectivity of FOXO4-DRI: non-senescent cells express little FOXO4 and therefore have minimal FOXO4-p53 interaction to disrupt.

3.2 FOXO4-DRI Competitive Disruption

FOXO4-DRI functions as a competitive inhibitor of the FOXO4-p53 interaction. The peptide corresponds to a fragment of the FOXO4 protein encompassing the p53-binding interface, but synthesized using the D-retro-inverso strategy. By mimicking the FOXO4 binding surface, FOXO4-DRI competes with endogenous FOXO4 for p53 binding, effectively dissociating the FOXO4-p53 complex within PML bodies [1][15].

Once released from FOXO4-mediated nuclear sequestration, p53 undergoes nuclear exclusion -- it is actively transported out of the nucleus. Free p53 then translocates to the outer mitochondrial membrane, where it triggers the intrinsic (mitochondrial) apoptotic pathway. This involves cytochrome c release from mitochondria into the cytoplasm, activation of the caspase cascade (specifically caspase-3 and caspase-7), and ultimately programmed cell death [1][3]. The 2025 Nature Communications study by Bourgeois et al. provided atomic-resolution NMR structures of the p53 TAD in complex with both the FOXO4 forkhead domain and FOXO4-DRI, revealing that both the FOXO4-derived region and the cationic cell-penetrating peptide portion of FOXO4-DRI contribute to p53 binding, and that p53 phosphorylation (particularly at serine 15) enhances the affinity for both FOXO4 and FOXO4-DRI [15].

3.3 D-Retro-Inverso Design Rationale

The DRI approach addresses a fundamental challenge in peptide therapeutics: the rapid proteolytic degradation of natural L-peptides in biological systems. In a retro-inverso peptide, two simultaneous modifications are made [1]:

1. Retro (sequence reversal): The amino acid sequence is reversed from C-to-N compared to the parent L-peptide.
2. Inverso (D-amino acid substitution): All L-amino acids are replaced with their D-enantiomers.

The combined effect of these modifications is that the side chain topology (the spatial arrangement of R-groups) is approximately preserved relative to the parent L-peptide, maintaining binding affinity for the target, while the amide backbone geometry is reversed. Because endogenous proteases recognize and cleave peptide bonds between L-amino acids in the natural N-to-C orientation, DRI peptides are largely invisible to the proteolytic machinery, resulting in dramatically extended biological half-life and improved bioavailability following injection [1].

The FOXO4-DRI sequence (H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH, where lowercase letters denote D-amino acids) spans 46 residues and includes a polyarginine-rich C-terminal segment that functions as a cell-penetrating peptide (CPP), facilitating cellular uptake [1][15].

4. The Baar et al. 2017 Landmark Study

The foundational study for FOXO4-DRI was published by Baar, Brandt, Putavet, and colleagues in Cell in March 2017, with Peter de Keizer as senior author [1]. This paper introduced the concept of Targeted Apoptosis of Senescent Cells (TASC) and demonstrated efficacy across three independent in vivo senescence models:

4.1 Doxorubicin Chemotoxicity Model

Doxorubicin, a widely used chemotherapy agent, induces profound cellular senescence as a side effect, contributing to long-term toxicities in cancer survivors. In mice treated with doxorubicin, FOXO4-DRI administration (5 mg/kg, three intravenous or intraperitoneal injections on alternate days) neutralized chemotherapy-induced weight loss, reduced plasma AST (a marker of liver damage), and eliminated senescence-associated FOXO4 foci in liver tissue. Importantly, FOXO4-DRI did not predispose healthy cells to DNA damage but selectively targeted cells that had already undergone senescence as a consequence of doxorubicin exposure [1].

4.2 Fast-Aging XpdTTD/TTD Mice

XpdTTD/TTD mice carry mutations in the ERCC2/XPD DNA repair gene and develop premature aging phenotypes recapitulating trichothiodystrophy. Treatment with FOXO4-DRI restored running wheel activity (from a baseline of approximately 1.4 km/day), improved fur density, and normalized plasma urea levels (indicating restored renal filtration capacity) [1].

4.3 Naturally Aged Wild-Type Mice

In wild-type mice aged 115-130 weeks (approximately 2.5 years), FOXO4-DRI treatment produced striking improvements in multiple aging phenotypes. Fur density increased visibly, with hair regrowth observable within 10 days of treatment. Kidney function was restored, as measured by normalization of plasma urea levels. Physical responsiveness to gentle stimuli improved substantially. These effects were comparable to those achieved by genetic senescent cell clearance using ganciclovir in p16::3MR reporter mice [1].

4.4 Safety Profile

A critical finding of the Baar et al. study was that FOXO4-DRI did not cause thrombocytopenia -- platelet counts remained unchanged after 30 days of treatment [1]. This stands in sharp contrast to navitoclax (ABT-263), whose clinical utility is severely limited by dose-dependent thrombocytopenia resulting from BCL-XL inhibition in platelets [13][20]. The selectivity of FOXO4-DRI for senescent cells, based on differential FOXO4 expression rather than broadly expressed anti-apoptotic proteins, provides a mechanistic basis for this favorable safety profile.

5. Subsequent Preclinical Studies

5.1 Age-Related Testosterone Deficiency

Zhang et al. (2020) demonstrated that FOXO4-DRI could address age-related testosterone secretion insufficiency by targeting senescent Leydig cells in the testes [4]. FOXO4 was found to be specifically expressed in human Leydig cells, with nuclear translocation increasing in elderly tissue and correlating with decreased testosterone synthesis. In naturally aged mice (20-24 months), FOXO4-DRI treatment (5 mg/kg IP, three doses on alternate days) selectively induced apoptosis of senescent Leydig cells, improved the testicular microenvironment, and significantly increased serum testosterone levels measured 30 days post-treatment [4].

5.2 Chondrocyte Rejuvenation

Huang et al. (2021) applied FOXO4-DRI to the problem of senescence accumulation during in vitro expansion of human chondrocytes for autologous chondrocyte implantation (ACI) [5]. At 25 micromolar concentration over 5 days, FOXO4-DRI significantly reduced cell numbers in high-passage senescent chondrocytes (PDL9) while having no effect on viability in low-passage cells (PDL3), demonstrating clear selectivity. Notably, navitoclax (ABT-263) failed to achieve significant senolytic effects in this same model, underscoring the context-dependent efficacy of different senolytic approaches [5].

5.3 Pulmonary Fibrosis

Han et al. (2022) tested FOXO4-DRI in a bleomycin-induced pulmonary fibrosis mouse model [8]. Treatment decreased senescent cell numbers, downregulated SASP expression, attenuated morphological changes and collagen deposition, and remodeled the cellular composition of the lung -- increasing type 2 alveolar epithelial cells while selectively eliminating myofibroblasts. FOXO4-DRI worked through the ECM-receptor interaction pathway and showed efficacy comparable to pirfenidone, an approved antifibrotic drug [8].

5.4 Keloid Scarring

Li et al. (2025) used single-cell RNA sequencing to identify increased pro-inflammatory and senescent fibroblast subpopulations in keloid tissue and showed that FOXO4-DRI promoted apoptosis of senescent keloid fibroblasts while decreasing G0/G1-phase cells [16]. The mechanism involved promotion of nuclear exclusion of p53 phosphorylated at serine 15 (p53-pS15), connecting the known FOXO4-p53 disruption mechanism to specific post-translational modifications relevant to keloid pathobiology [16].

5.5 Vascular Aging and Endothelial Senescence

Wang et al. (2025) demonstrated that FOXO4-DRI could suppress aortic aging and improve aortic function in both naturally aged and induced-aging mice [17]. In vitro, the peptide alleviated endothelial cell senescence induced by oxygen-glucose deprivation, supporting a role for FOXO4-p53-mediated senescence in vascular dysfunction during aging [17].

5.6 Next-Generation Peptides: ES2 and Optimized Variants

Marchetti et al. (2021) used molecular modeling of the FOXO4-TP53 interface to rationally design improved senolytic peptides [6][7]. The resulting ES2 peptide series demonstrated 3 to 7 times greater senolytic activity than FOXO4-DRI in both in vitro and in vivo models, while maintaining selectivity for senescent over proliferating cells. ES2 peptides disrupted FOXO4-TP53 foci, activated TP53-mediated apoptosis, and preferentially eliminated senescent cancer cells in orthotopic mouse models [6][7]. A 2024 bioRxiv preprint further refined peptide inhibitors targeting the FOXO4-p53 interaction with enhanced potency for senescent cancer cell-specific apoptosis.

5.7 Structural Biology of the FOXO4-DRI-p53 Complex

The 2025 Nature Communications study by Bourgeois et al. provided the first high-resolution structural characterization of how FOXO4-DRI engages p53 [15]. Using solution NMR spectroscopy, the authors solved structural models of the disordered p53 transactivation domain (TAD) bound to both the FOXO4 forkhead domain and to FOXO4-DRI. Key findings included that the disordered FOXO4-DRI forms a transiently folded complex with the disordered p53 TAD2 subdomain, that both the FOXO4-derived region and the cationic cell-penetrating peptide tail contribute to binding, and that phosphorylation of p53 enhances affinity for both FOXO4 and FOXO4-DRI [15]. These structural insights provide a rational basis for designing next-generation senolytics with optimized target engagement.

6. Comparison with Other Senolytics

| Feature | FOXO4-DRI | Navitoclax (ABT-263) | Dasatinib + Quercetin | |---|---|---|---| | Mechanism | Disrupts FOXO4-p53 interaction in PML bodies | Inhibits BCL-2/BCL-XL/BCL-W anti-apoptotic proteins | Dasatinib: tyrosine kinase inhibitor; Quercetin: PI3K/serpine inhibitor | | Selectivity | High (FOXO4 upregulated specifically in senescent cells) | Low-moderate (BCL-XL expressed in platelets, lymphocytes) | Low-moderate (targets broadly expressed pathways) | | Thrombocytopenia | Not observed in preclinical studies [1] | Dose-limiting toxicity (BCL-XL in platelets) [13][20] | Not a primary concern at senolytic doses | | Molecule type | 46-AA D-retro-inverso peptide (~5.4 kDa) | Small molecule (MW 979 Da) | Small molecule combination | | Route | Injection (IV/IP); not orally bioavailable | Oral | Oral | | Clinical status | Preclinical only | Phase 3 (myelofibrosis) | Phase 1/2 completed (diabetic kidney disease, Alzheimer disease) [14] | | Key limitation | Requires injection; high synthesis cost; limited PK data | Severe thrombocytopenia; neutropenia | Non-selective; variable efficacy across senescent cell types |

The first open-label human pilot study of senolytics used dasatinib+quercetin in patients with diabetic kidney disease and demonstrated decreased senescent cell burden, reduced SASP factors, and improved adipose tissue function, establishing proof-of-concept that pharmacological senolysis is achievable in humans [14]. No comparable human data exists for FOXO4-DRI. Navitoclax has advanced furthest clinically but in oncology (myelofibrosis) rather than aging indications, and its senolytic potential remains limited by hematological toxicity [13][20].

7. Clinical Evidence Summary

8. Dosing in Research

The following table summarizes doses used in published preclinical research studies. These are not therapeutic recommendations. FOXO4-DRI is not approved for human use and has not been evaluated in human clinical trials.

9. Safety and Unknowns

9.1 Preclinical Safety Data

In the Baar et al. 2017 study, FOXO4-DRI treatment at 5 mg/kg (three doses on alternate days) in mice did not cause thrombocytopenia, and platelet levels remained stable over a 30-day observation period [1]. No significant toxicity was observed in non-senescent TM3 Leydig cells, where FOXO4 expression was low [4]. In pulmonary fibrosis models, FOXO4-DRI showed a tolerability profile comparable to pirfenidone [8].

9.2 Unresolved Safety Questions

Despite encouraging preclinical data, significant safety unknowns remain:

• No human pharmacokinetic data: The half-life, biodistribution, tissue penetration, and clearance of FOXO4-DRI in humans have not been characterized. The peptide is not orally bioavailable and requires parenteral administration.
• Potential stress to non-senescent cells: Zhang et al. noted increased p21 levels in FOXO4-DRI pre-treatment groups, suggesting the compound might act as a mild stressor to cells, potentially inducing low-level senescence that could complicate repeated dosing regimens [4].
• Long-term consequences of senescent cell clearance: Some senescent cells serve beneficial roles in wound healing, tissue repair, and tumor suppression. The consequences of repeated or aggressive senolytic therapy on these protective functions are not fully understood [9][10].
• Immune system effects: Senescent cells interact extensively with the immune system, and their acute elimination could trigger inflammatory responses from the release of intracellular contents or from disruption of immunosurveillance programs.
• Off-target p53 modulation: While FOXO4-DRI selectivity depends on differential FOXO4 expression, the potential for the peptide to interact with p53 in contexts outside the FOXO4-p53 complex has not been exhaustively evaluated.
• Synthesis purity and consistency: As a 46-residue peptide requiring all-D-amino acid synthesis, FOXO4-DRI is technically challenging to manufacture. Quality variation in research-grade material could affect reproducibility of results.

9.3 Planned Clinical Development

De Keizer has indicated plans to conduct initial human safety testing in patients with glioblastoma multiforme, an aggressive brain tumor that exhibits high levels of the senescence biomarkers relevant to FOXO4-DRI activity [2]. As of 2026, no clinical trial registrations for FOXO4-DRI or Proxofim appear on ClinicalTrials.gov.

10. Regulatory Status

United States (FDA): FOXO4-DRI is not approved for any therapeutic indication. It is classified as a research compound. No Investigational New Drug (IND) application has been publicly reported.

European Medicines Agency (EMA): No regulatory submissions for FOXO4-DRI are publicly recorded.

Research availability: FOXO4-DRI is available from multiple peptide synthesis vendors for research purposes. It is sold exclusively for laboratory and investigational use, not for human consumption.

11. Pharmacokinetics

11.1 D-Retro-Inverso Protease Resistance

The defining pharmacokinetic feature of FOXO4-DRI is the protease resistance conferred by its all-D-amino-acid, retro-inverso architecture. Endogenous proteases -- including trypsin, chymotrypsin, pepsin, and the broad spectrum of tissue peptidases -- have evolved to recognize and cleave peptide bonds between L-amino acids in the natural N-to-C orientation. By reversing the sequence and substituting all L-amino acids with D-enantiomers, FOXO4-DRI renders itself essentially invisible to these enzymes [1][3]. This results in dramatically extended biological persistence compared to an equivalent L-peptide of the same sequence, which would be degraded within minutes in plasma.

No formal pharmacokinetic studies (Cmax, Tmax, AUC, clearance, volume of distribution) have been published for FOXO4-DRI in any species. The absence of quantitative PK data represents a significant gap in the preclinical characterization of this compound.

11.2 Estimated Half-Life and Persistence

While the exact plasma half-life of FOXO4-DRI has not been measured, several lines of evidence support a substantially extended duration of action:

• D-amino acid stability precedent: Other D-retro-inverso peptides and all-D peptides in the literature have demonstrated plasma half-lives ranging from hours to days, compared to minutes for their L-counterparts. For a 46-residue all-D peptide with no recognized protease cleavage sites, a half-life measured in days rather than hours is expected.
• Functional duration: In the Baar et al. 2017 study, three doses of FOXO4-DRI (5 mg/kg on days 1, 3, and 5) produced biological effects that persisted for at least 30 days post-treatment, including sustained platelet stability and continued fur regrowth [1]. Zhang et al. (2020) measured testosterone increases 30 days after the same three-dose regimen [4]. This sustained pharmacodynamic activity is consistent with either a long half-life or an irreversible mechanism of action at the cellular level (once a senescent cell is eliminated, the effect persists regardless of drug clearance).
• Renal clearance: At approximately 5,358 Da, FOXO4-DRI is below the glomerular filtration molecular weight cutoff (approximately 60,000 Da) and would be expected to undergo renal clearance. However, the polyarginine C-terminal cell-penetrating peptide sequence may promote tissue binding and reduce renal elimination rate.

11.3 Biodistribution and Tissue Penetration

No biodistribution studies have been published. The polyarginine-rich C-terminal sequence functions as a cell-penetrating peptide (CPP), facilitating cellular uptake across cell membranes through both energy-dependent (endocytosis) and energy-independent (direct translocation) mechanisms [1][15]. This CPP domain is critical for the biological activity of FOXO4-DRI, as the peptide must enter the cell and reach the nucleus to disrupt the FOXO4-p53 interaction in PML bodies.

The 2025 NMR structural study by Bourgeois et al. revealed that the CPP tail contributes not only to cellular uptake but also to p53 binding, indicating that this sequence serves a dual function: delivery and target engagement [15]. This finding suggests that FOXO4-DRI's biodistribution would be influenced by cell-surface heparan sulfate proteoglycans (the primary binding partners for polyarginine CPPs) and intracellular p53/FOXO4 expression levels.

11.4 Route of Administration Constraints

FOXO4-DRI is not orally bioavailable due to its large molecular weight (5,358 Da), high hydrophilicity, and polyarginine content. All published studies have used parenteral administration (intravenous or intraperitoneal injection) [1][4][8]. Subcutaneous administration has not been formally evaluated but would be expected to provide adequate absorption given the peptide's solubility profile. The requirement for injection administration limits the practical utility of FOXO4-DRI compared to orally available senolytics like dasatinib+quercetin.

12. Dose-Response Relationships

12.1 In Vitro Senolytic Dose-Response

Huang et al. (2021) provided the most informative in vitro dose-response data in human chondrocytes [5]:

• 25 micromolar FOXO4-DRI: Significantly reduced cell number in high-passage senescent chondrocytes (PDL9) while having no effect on low-passage (PDL3) non-senescent cells
• Selectivity window: The senolytic effect was observed only in cells with high senescence burden (confirmed by SA-beta-gal staining and p16/p21 expression), demonstrating a clear therapeutic window based on cellular senescence status rather than drug concentration alone

The Baar et al. 2017 study used FOXO4-DRI at concentrations of 12.5-50 micromolar in cell culture experiments with senescent IMR90 fibroblasts, observing dose-dependent increases in caspase-3/7 activity and apoptosis specifically in senescent (but not proliferating) cells [1]. The EC50 for selective senescent cell killing in vitro has not been formally determined but appears to be in the 10-25 micromolar range based on available data.

12.2 In Vivo Dose Selection

All published in vivo studies have used a single dose level of 5 mg/kg, administered as three injections on alternate days (days 1, 3, 5):

• Baar et al. 2017: 5 mg/kg IV or IP in fast-aging mice, doxorubicin-treated mice, and naturally aged mice [1]
• Zhang et al. 2020: 5 mg/kg IP in naturally aged mice [4]
• Han et al. 2022: FOXO4-DRI in bleomycin-induced pulmonary fibrosis model [8]

The absence of dose-escalation studies is a significant limitation. Whether lower doses (1-2 mg/kg) would retain senolytic efficacy with potentially fewer off-target effects, or whether higher doses (10-20 mg/kg) would improve clearance of resistant senescent cell populations, is entirely unknown. The consistent use of 5 mg/kg across studies appears to reflect adoption of the original Baar et al. protocol rather than optimization through formal dose-finding.

12.3 Intermittent Dosing Rationale

The three-dose, alternate-day regimen used across studies reflects the "hit-and-run" senolytic dosing concept: because senescent cells, once eliminated, do not regenerate immediately, senolytics can theoretically be given in short pulses rather than continuously [1][2]. The 30-day post-treatment assessments in multiple studies confirm that biological effects persist well beyond the treatment period, supporting this intermittent dosing approach.

However, the optimal dosing interval for repeated senolytic cycles has not been determined. De novo senescent cells continue to form through ongoing aging processes and DNA damage, and the rate of senescent cell reaccumulation after clearance is unknown. Whether FOXO4-DRI should be administered monthly, quarterly, or annually for sustained anti-aging effects remains entirely speculative.

12.4 Next-Generation Potency

Marchetti et al. (2021) demonstrated that rationally designed ES2 peptides showed 3-7 times greater senolytic activity than FOXO4-DRI in both in vitro and in vivo models [6][7]. This suggests that the original FOXO4-DRI dose may not represent the optimal potency achievable through the FOXO4-p53 disruption mechanism, and that improved variants could potentially achieve equivalent senolysis at lower doses with potentially improved therapeutic windows.

13. Comparative Effectiveness

13.1 FOXO4-DRI versus Navitoclax (ABT-263)

Navitoclax is the most extensively studied preclinical senolytic after dasatinib+quercetin:

Mechanism: Navitoclax inhibits BCL-2, BCL-XL, and BCL-W anti-apoptotic proteins that are upregulated in senescent cells, releasing pro-apoptotic BAX and BAK to trigger mitochondrial apoptosis [13][20]. FOXO4-DRI disrupts the FOXO4-p53 interaction, releasing p53 to trigger mitochondrial apoptosis through a distinct upstream pathway [1].

Selectivity: Navitoclax's target, BCL-XL, is broadly expressed in non-senescent cells, particularly platelets, lymphocytes, and neurons. This causes dose-limiting thrombocytopenia (platelet counts can decrease by 50-70%) and lymphopenia [13][20]. FOXO4-DRI does not cause thrombocytopenia because FOXO4 is upregulated specifically in senescent cells [1]. In the Huang et al. (2021) chondrocyte study, navitoclax failed to show significant senolytic effects while FOXO4-DRI was clearly effective, demonstrating context-dependent superiority [5].

Clinical advancement: Navitoclax has advanced further clinically, with Phase 3 trials in myelofibrosis (an oncology, not aging, indication). FOXO4-DRI has no clinical trial registrations.

Practical considerations: Navitoclax is an orally bioavailable small molecule (MW 979 Da), making it more practical to administer than the injectable FOXO4-DRI (MW 5,358 Da). Cost of synthesis favors navitoclax substantially.

13.2 FOXO4-DRI versus Dasatinib + Quercetin (D+Q)

D+Q is the only senolytic combination with published human clinical data:

Human evidence: Hickson et al. (2019) demonstrated in an open-label pilot study that D+Q decreased senescent cell burden, reduced SASP factors, and improved adipose tissue function in patients with diabetic kidney disease [14]. No human data exist for FOXO4-DRI.

Mechanism breadth: D+Q targets multiple senescent cell anti-apoptotic pathways (SCAPs) -- dasatinib inhibits multiple tyrosine kinases (including ephrin receptors and Src family kinases) while quercetin inhibits PI3K, serpines, and BCL-XL [12]. This broad targeting may explain D+Q's effectiveness across diverse senescent cell types but also reduces selectivity. FOXO4-DRI targets a single, well-defined interaction (FOXO4-p53) with potentially greater selectivity but potentially narrower efficacy across senescent cell subtypes.

Tolerability: D+Q at senolytic doses (dasatinib 100 mg + quercetin 1000 mg, intermittent dosing) was generally well tolerated in the Hickson pilot study [14]. FOXO4-DRI tolerability in humans is unknown.

Accessibility: Dasatinib is an FDA-approved cancer drug available by prescription, and quercetin is a dietary supplement, making D+Q relatively accessible. FOXO4-DRI requires custom peptide synthesis and injection.

13.3 FOXO4-DRI versus Fisetin

Fisetin, a natural flavonoid found in strawberries and other fruits, was identified as a senotherapeutic by Yousefzadeh et al. (2018) [21]:

• Evidence: Fisetin extended health span and lifespan in mice when administered late in life. It reduced senescent cell markers in multiple tissues and decreased SASP-related inflammation [21].
• Mechanism: Fisetin's senolytic mechanism is less precisely defined than FOXO4-DRI's, likely involving PI3K/AKT and mTOR pathway modulation and possibly BCL-2 family targeting.
• Practicality: Fisetin is orally bioavailable, inexpensive, widely available as a dietary supplement, and has a favorable safety profile from extensive human consumption. However, its bioavailability is limited (approximately 44% in rodent studies), and optimal human senolytic doses have not been established.
• Selectivity: Fisetin is less selective than FOXO4-DRI for senescent cells and has broader biological activities including antioxidant, anti-inflammatory, and neuroprotective effects unrelated to senolysis [21].

13.4 Unique Advantages of FOXO4-DRI

Despite its practical limitations (injection-only, high synthesis cost, no human data), FOXO4-DRI possesses several unique mechanistic advantages:

1. Highest reported selectivity: The dependence on senescent-cell-specific FOXO4 upregulation provides a selectivity mechanism absent from all other senolytics
2. No platelet toxicity: Unlike navitoclax and potentially other BCL-2-targeting senolytics
3. Defined molecular target: The FOXO4-p53 interaction is structurally characterized (2025 NMR data), enabling rational optimization [15]
4. Orthogonal mechanism: Can potentially be combined with D+Q or other senolytics targeting different SCAP pathways for enhanced senescent cell clearance

14. Enhanced Safety Profile

14.1 Preclinical Safety Evidence

The available preclinical safety data for FOXO4-DRI, while limited, are consistently favorable:

• Platelet safety: Platelet counts remained stable over 30 days post-treatment in the Baar et al. study, distinguishing FOXO4-DRI from navitoclax [1]
• Non-senescent cell sparing: In vitro, FOXO4-DRI showed no effect on viability of proliferating or quiescent cells in multiple cell types (IMR90 fibroblasts, chondrocytes, Leydig cells) [1][4][5]
• Organ function preservation: Kidney function improved (plasma urea normalization) rather than deteriorated following treatment in aged mice [1]
• Liver safety: AST levels decreased in doxorubicin-treated mice, indicating liver protective rather than hepatotoxic effects [1]
• Comparable tolerability to pirfenidone: In the pulmonary fibrosis model, FOXO4-DRI showed a tolerability profile similar to the approved antifibrotic drug pirfenidone [8]

14.2 Theoretical Risks from Senescent Cell Clearance

The most significant safety concern with any senolytic, including FOXO4-DRI, is the potential consequence of eliminating cells that serve beneficial functions:

Wound healing: Senescent cells contribute to wound healing through SASP-mediated paracrine signaling to neighboring cells, including recruitment of immune cells and stimulation of myofibroblast differentiation. Aggressive senolytic therapy during active wound healing could theoretically impair repair [9][10].

Tumor suppression: Cellular senescence is a primary tumor-suppressive mechanism that halts proliferation of cells with oncogenic mutations or DNA damage. Eliminating senescent cells could theoretically remove this protective barrier, though the countervailing argument is that the SASP from accumulated senescent cells paradoxically promotes tumorigenesis in surrounding cells [10][18].

Immune function: Senescent immune cells (immunosenescence) contribute to age-related immune decline, but acute elimination of these cells could temporarily compromise immune surveillance. The interaction between senolytic therapy and immune function in aging is poorly understood [10].

14.3 p53 Modulation Risks

FOXO4-DRI acts by releasing p53 from FOXO4-mediated sequestration. While selectivity depends on differential FOXO4 expression, the potential for the peptide to interact with p53 in non-senescent contexts has not been exhaustively evaluated [1][3]. The 2025 Bourgeois et al. structural study showed that the CPP tail of FOXO4-DRI contributes to p53 binding, raising the question of whether nonspecific electrostatic interactions between the polyarginine CPP and other cellular proteins could produce off-target effects at high concentrations [15].

Zhang et al. (2020) noted that FOXO4-DRI pre-treatment groups showed increased p21 levels, suggesting the compound might act as a mild stressor to non-senescent cells [4]. Whether this low-level p21 induction could paradoxically promote senescence in previously healthy cells with repeated dosing cycles is a concern that remains unaddressed.

14.4 Synthesis and Quality Considerations

FOXO4-DRI's 46-residue length with all-D-amino acids makes it one of the most technically challenging peptides to synthesize with high purity. Issues include:

• Deletions and truncations during solid-phase synthesis
• Racemization at individual residues
• Aggregation of the polyarginine C-terminal domain
• Difficulty achieving purities above 95% at commercial scale

Quality variation in research-grade material available from peptide synthesis vendors could affect reproducibility of preclinical results and introduces uncertainty about the compound being tested in any given study [1]. Clinical-grade FOXO4-DRI would require extensive analytical characterization, GMP synthesis, and stability testing that have not been publicly reported.

14.5 Absence of Formal Toxicology

No formal toxicology studies have been published for FOXO4-DRI:

• No maximum tolerated dose (MTD) determination
• No NOAEL (no-observed-adverse-effect level) establishment
• No reproductive or developmental toxicity assessment
• No carcinogenicity or genotoxicity testing
• No immunogenicity evaluation (the all-D structure may reduce but not eliminate antibody responses to chronic administration)

This absence of standard preclinical safety data means that the safety profile of FOXO4-DRI cannot be properly characterized beyond the limited observations from efficacy studies. Formal IND-enabling toxicology studies would be required before any human clinical testing could proceed.

15. Related Peptides

See also: Epithalon (Epitalon), Humanin, MOTS-c

16. References

1. [1] Baar MP, Brandt RMC, Putavet DA, et al. (2017). Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. DOI PubMed
2. [2] de Keizer PLJ. (2017). Rejuvenation by therapeutic elimination of senescent cells. Cell. DOI PubMed
3. [3] Bourgeois B, Bhatt K, Bhatt Y, et al. (2018). Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Letters. DOI PubMed
4. [4] Zhang C, Xie Y, Chen H, et al. (2020). FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). DOI PubMed
5. [5] Huang J, He Y, Makarcyzk MJ, Lin H. (2021). Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes. Frontiers in Bioengineering and Biotechnology. DOI PubMed
6. [6] Marchetti L, Bottelli S, Giordano A, Bhatt K. (2021). Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. eBioMedicine. DOI PubMed
7. [7] Marchetti L, Bottelli S, Bhatt K, et al. (2021). Development of a novel senolytic by precise disruption of FOXO4-p53 complex. eBioMedicine. DOI PubMed
8. [8] Han L, Zhang Y, Wan S, et al. (2022). FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Journal of Cellular and Molecular Medicine. DOI PubMed
9. [9] van Deursen JM. (2014). The role of senescent cells in ageing. Nature. DOI PubMed
10. [10] Childs BG, Durik M, Baker DJ, van Deursen JM. (2015). Cellular senescence in aging and age-related disease. Nature Medicine. DOI PubMed
11. [11] Baker DJ, Childs BG, Durik M, et al. (2016). Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature. DOI PubMed
12. [12] Zhu Y, Tchkonia T, Pirtskhalava T, et al. (2015). The Achilles heel of senescent cells -- from transcriptome to senolytic drugs. Aging Cell. DOI PubMed
13. [13] Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, et al. (2016). Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. DOI PubMed
14. [14] Hickson LJ, Langhi Prata LGP, Boez SA, et al. (2019). Senolytics decrease senescent cells in humans -- first open-label pilot study. eBioMedicine. DOI PubMed
15. [15] Bourgeois B, Gui T, Brunner D, et al. (2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications. DOI PubMed
16. [16] Li Y, Zhao Q, Liu Y, et al. (2025). FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications Biology. DOI PubMed
17. [17] Wang L, Chen X, et al. (2025). FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in Bioengineering and Biotechnology. DOI PubMed
18. [18] Coppe JP, Desprez PY, Krtolica A, Campisi J. (2010). The senescence-associated secretory phenotype -- the dark side of tumor suppression. Annual Review of Pathology. DOI PubMed
19. [19] Xu M, Pirtskhalava T, Farr JN, et al. (2018). Senolytics improve physical function and increase lifespan in old age. Nature Medicine. DOI PubMed
20. [20] Chang J, Wang Y, Shao L, et al. (2016). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine. DOI PubMed
21. [21] Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. (2018). Fisetin is a senotherapeutic that extends health span and lifespan. eBioMedicine. DOI PubMed
22. [22] Bourgeois B, Bhatt K, et al. (2021). Biophysical investigation of the dual binding surfaces of human transcription factors FOXO4 and p53. bioRxiv (preprint). DOI PubMed